Condition: Myelofibrosis (PMF) · Post Essential Thrombocythemia Myelofibrosis (ET-MF) · Post Polycythemia Vera Related Myelofibrosis (PV-MF) · Sponsor: Icahn School of Medicine at Mount Sinai
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). After cycle 6, patients may continue receiving reparixin once daily on a 4-week cycle if at least stable disease (SD) is met by IWG-MRT criteria until loss of response, disease progression, unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.
This description comes directly from the study's public registry record.
Gillian Sanchez · (917) 581-1774 · gillian.sanchez@mssm.edu
Shakira Forde · 212-824-8334 · shakira.forde@mssm.edu
Always discuss trial participation with your own doctor first.
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Roswell Park Cancer Institute | Buffalo, New York, United States | Recruiting |
| Ruttenberg Treatment Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| NewYork-Presbyterian/Weill Cornell Medical Center | New York, New York, United States | Recruiting |
| Wake Forest Baptist Health Comprehensive Cancer Center | Winston-Salem, North Carolina, United States | Recruiting |
| The Cleveland Clinic Foundation | Cleveland, Ohio, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05835466